MitoTALENs: A general approach to reduce mutant mtDNA loads and restore oxidative phosphorylation function in mitochondrial diseases by Hashimoto, Masami et al.
 © 2015 The American Society of Gene & Cell Therapy. All rights reserved 
ACCEPTED ARTICLE PREVIEW 
MitoTALENs: A general approach to reduce mutant mtDNA loads 
and restore oxidative phosphorylation function in mitochondrial 
diseases 
 
 
Masami Hashimoto, Sandra R. Bacman, Susana Peralta, Marni J. 
Falk, Anne Chomyn, David C. Chan, Sion L. Williams, Carlos T. 
Moraes 
 
Cite this article as: Masami Hashimoto, Sandra R. Bacman, Susana Peralta, Marni J. Falk, Anne 
Chomyn, David C. Chan, Sion L. Williams, Carlos T. Moraes, MitoTALENs: A general approach to 
reduce mutant mtDNA loads and restore oxidative phosphorylation function in mitochondrial 
diseases, Molecular Therapy accepted article preview online 10 July 2015; doi:10.1038/mt.2015.126 
 
This is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication. 
NPG is providing this early version of the manuscript as a service to our customers. The manuscript 
will undergo copyediting, typesetting and a proof review before it is published in its final form. 
Please note that during the production process errors may be discovered which could affect the 
content, and all legal disclaimers apply. 
 
Received 22 April 2015; accepted 21 June 2015; Accepted article preview online 10 July 2015 
 
Accepted Article Preview: Published ahead of advance online publication 
Ac
ce
pte
d
an
us
cri
pt
ACCEPTED ARTICLE PREVIEW 
© 2015 The American Society of Gene & Cell Therapy. All rights reserved 
MitoTALEN: A general approach to reduce mutant mtDNA loads and restore 
oxidative phosphorylation function in mitochondrial diseases  
 
Masami Hashimoto, Ph.D.*1, Sandra R. Bacman, Ph.D.*1, Susana Peralta, Ph.D.1, Marni J. Falk, M.D.2, 
Anne Chomyn Ph.D.3, David C. Chan, M.D., Ph.D.3, Sion L. Williams, Ph.D.1,4, Carlos T. Moraes, 
Ph.D.1,5,# 
 
1Department of Neurology, University of Miami: Miller School of Medicine Miami, Miami, FL  
2Division of Human Genetics, Department of Pediatrics, The Children's Hospital of Philadelphia and 
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 
3Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 
4Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL  
5Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL  
 
* Co-First authors (equal contribution) 
#Correspondence should be addressed to: Carlos T. Moraes,  
1420 NW 9th Ave, Miami, FL  33136 
Phone: (305) 243-5858 
Email: cmoraes@med.miami.edu 
 
Running title: MitoTALENS as therapy for mitochondrial diseases 
Ac
ce
pte
d m
an
us
cri
pt
ACCEPTED ARTICLE PREVIEW 
© 2015 The American Society of Gene & Cell Therapy. All rights reserved 
 
Abstract 
We have designed mitochondrially targeted Transcription Activator-Like Effector Nucleases or 
mitoTALENs to cleave specific sequences in the mitochondrial DNA (mtDNA) with the goal of 
eliminating mtDNA carrying pathogenic point mutations. To test the generality of the approach we 
designed mitoTALENs to target two relatively common pathogenic mtDNA point mutations associated 
with mitochondrial diseases: the m.8344A>G tRNALys gene mutation associated with Myoclonic 
Epilepsy with Ragged-Red Fibers (MERRF) and the m.13513G>A ND5 mutation associated with 
MELAS/Leigh Syndrome. Transmitochondrial cybrid cells harbouring the respective heteroplasmic 
mtDNA mutations were transfected with the respective mitoTALEN and analysed after different time 
periods. MitoTALENs efficiently reduced the levels of the targeted pathogenic mtDNAs in the 
respective cell lines. Functional assays showed that cells with heteroplasmic mutant mtDNA were able 
to recover respiratory capacity and oxidative phosphorylation enzymes activity after transfection with 
the mitoTALEN. To improve the design in the context of the low complexity of mtDNA, we designed 
shorter versions of the mitoTALEN specific for the MERRF m.8344A>G mutation. These shorter 
mitoTALENs also eliminated the mutant mtDNA. These reductions in size improve our ability to 
package these large sequences into viral vectors, bringing the use of these genetic tools closer to clinical 
trials. Ac
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Introduction 
 Mitochondrial diseases impairing oxidative phosphorylation (OXPHOS) can affect multiple 
organs or single ones and can be caused by mutations in nuclear genes or in the mitochondrial DNA 
(mtDNA). Mutations in mtDNA are commonly in a heteroplasmic state, where mutant mtDNA co-exists 
with wild-type. There are approximately 1,000 mtDNA molecules in a cell, and the wild-type mtDNA 
can compensate for the presence of mutant mtDNA, up to threshold levels, which are usually relatively 
high, 70-95% [1-3]. This “recessive” feature of the mutant mtDNA means that by simply reducing the 
relative levels of mutant mitochondrial genomes, biochemical defects can be reversed.  
TALENs are engineered nucleases based on the TALE DNA-binding domain from Xanthomonas 
fused to a FokI type-II nuclease domain. Because the FokI domains need to dimerize to cleave DNA, 
two TALEN monomers are required to bind adjacent recognition sequences on opposing sense/antisense 
strands of DNA [4, 5]. The DNA binding specificity of TALE domains is given by tandem copies of 34 
amino acid repeats that each preferentially bind one of the four DNA bases depending on the amino 
acids at positions 12 and 13 of the repeat. The nucleotide affinity of these Repeat Variable Di-residues 
(RVDs) is well understood, providing the basis to engineer novel specificities [6, 7]. Because the last 
repeat contains only 20 amino acids (instead of 34), it is referred to as a 0.5 repeat. 
Commonly, 15.5-22.5 TALE repeats are used per monomer to avoid off-target cleavage [5, 8]. 
Although TALEN can be very specific for genetic loci, this specificity is not perfect and off-site 
cleavages, in large and complex genomes, are a concern [9]. Moreover, as mentioned above, the high 
specificity of TALENs is in great part due to the combination of both sequence specificity of TALE 
binding and the positional requirements of FokI cleavage. In this context, the ability of TALENs to 
differentiate targets with only single nucleotide differences is difficult.  
We have previously shown that for at least one point mutation (m.14459A>G), mitochondrial-
targeted TALEN (mitoTALEN) was able to reduce the mutation load [10]. This is compatible with our 
previous observation that the mutant mtDNA undergoing a double-strand break by restriction 
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endonucleases is followed by rapid degradation [11]. The mtDNA copy number control ensures that the 
residual (wild-type) intact mitochondrial genomes re-populate the cell [12]. 
To test whether expression of mitoTALEN could be a general approach for the reduction of the 
levels of mtDNA point mutations, we developed mitoTALENs for two relatively common pathogenic 
mtDNA mutations. One is the m.8344A>G mutation in the tRNA lysine gene that accounts for 80 to 
90% of cases presenting with Myoclonus Epilepsy with Ragged Red Fibers (MERRF) syndrome [13, 
14] and the other is the m.13513G>A mutation in the ND5 gene associated with MELAS/Leigh 
syndrome [15-17]. We have also explored the reduction of the size of the mitoTALEN monomers to 
optimize their use for gene therapy. 
 
Results 
Designing mitoTALENs 
We developed TALENs against two distinct mtDNA point mutations at positions m.8344A>G 
and m.13513G>A (Fig. 1). A required element for the binding of the N-terminus of most TALEN 
monomers is a T at position 0 in the DNA recognition sequence, immediately upstream (5’) to the region 
recognized by the RVDs [4, 7]. MtDNA has a well-recognized transition bias for naturally occurring 
point mutations (>90% transitions vs transversions [18]). For C>T and G>A “gain of T” transition 
mutations the requirement for T0 can be exploited to develop TALENs that can differentially recognize 
and cleave these mutations, as we have demonstrated in one previous case [10]. For the m.13513G>A 
mutation in ND5 we further explored the utility of this approach, designing two different TALENs 
where the differentiating monomer binding site included a T0 of the antisense strand at the G>A 
mutation (Fig. 1b and Supplementary Fig. S1). The two TALENs differed from each other by the 
numbers of RVD repeats for the monomer binding the mutation, one having 9.5 RVDs and the other 
12.5 RVDs. 
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Unfortunately, the m.8344A>G mutation does not allow for the use of T0 design strategy as it is 
a T>C, A>G mutation, i.e. “loss of T”. In the sense strand, the transition A>G posed a further challenge 
for the design, as the conventional RVD for binding G is “NN” which cannot discriminate between A 
and G effectively [4, 7], which constitute the wild-type and mutant alleles for this mutation. However, in 
the anti-sense strand, the mutant gains a C, which can be recognized more specifically by an “HD” RVD 
that does not effectively bind T (the base present in the wild type antisense). Therefore, for m.8344A>G, 
we chose to place the mutated G at position 3 of the antisense monomer, exploiting a “gain of C3” 
model (Fig. 1b). We developed two m.8344A>G TALEN pairs with this general design, the main 
difference being that the monomer binding the mutated region had either 9.5 RVDs or 15.5 RVDs 
(Supplementary Fig. S1). In both of them we designed the DNA binding domain to include the mutant G 
at position C3 of the antisense strand (Fig. 1 and Supplementary Fig. S1). These TALENs were initially 
tested in yeast Single-Strand Annealing assays. Because one of the pairs (version A) showed similar 
efficiency in the binding and cleavage of both mutant and wild-type target sequences (Supplementary 
Fig. S2), it was not used further and the subsequent experiments were performed with version B only 
(Fig. 1 and S2).  
For all TALENs the obligate heterodimeric FokI nuclease domains were used to reduce self-self 
offsite cleavage [19-21]. Monomers were re-engineered to contain a mitochondrial localization signal 
(MLS, from SOD2 or COX8A/Su9), a specific immunological tag (HA or FLAG), a poly(A)/3’ UTR 
(SOD2 or ATP5B), and a fluorescent marker (mCherry or eGFP), the latter being separated from the 
TALEN coding region by a T2A picornavirus ribosome stuttering sequence [10, 22]. Mitochondrial 
localization was verified by immunocytochemistry (Fig. 2). The presence of full-length proteins was 
determined by western blots (Fig. 2). Some of the monomers showed two bands in western blots, and 
mitochondrial isolation and treatment with proteinase K indicates that the higher MW band corresponds 
to a small fraction of the monomer harboring the COX8A/Su9 that remains attached to the outside of the 
mitochondria (Supplementary Fig. S3). Nonetheless, the mtDNA heteroplasmy changes (described 
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below) show that the MLS are able to localize the mitoTALENs in the mitochondrial matrix with access 
to the mtDNA. 
 
mitoTALENs promote a robust change in mtDNA heteroplasmy. 
 To test the efficacy of the mitoTALENs we produced transmitochondrial cybrid cell lines 
harboring different levels of the respective heteroplasmic mtDNA point mutations [23, 24]. Selected 
cybrid lines with a high level of mutant mtDNA were transfected with pairs of plasmids coding for each 
mitoTALEN monomer. Two days after transfection, cells were sorted for the fluorescent markers 
(mCherry and eGFP), and analyzed. Borrowing from the color effects seen in overlay images, cells 
expressing both green (eGFP) and red (mCherry) markers were termed “Yellow”, and cells sorted as 
negative for the markers were termed “Black” (Supplementary Fig. S4). Most of subsequent experiments 
herein compare Yellow and Black cell populations. Fig. 3a shows that the m.8344A>G mitoTALEN was 
able to markedly reduce the levels of mutant mtDNA in Yellow cells.  
Sorted cells were also cultured long term and we found that the robust change in mtDNA 
heteroplasmy levels in transmitochondrial cybrids (Fig. 3a), which was maintained over time (Fig. 3b). 
This finding is consistent with our previous study [10]. We did notice a slight drift towards increasing 
wild-type mtDNA levels over time, including in the Black cell population (Fig. 3b). We believe that the 
Black cell population may contain low levels of transfected cells and some cleavage of the mutant 
mtDNA may have occurred at low levels. 
 Both the 9.5 and 12.5 RVD mitoTALENs against the m.13513G>A mutation triggered a robust 
shift in heteroplasmy. Fig. 3c illustrates the heteroplasmy shift obtained with one of them (version B) 
and shows the quantitative determinations for both mitoTALEN versions. 
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Heteroplasmic cells treated with mitoTALEN improve their OXPHOS function. 
 To determine whether the change in heteroplasmy improved the biochemical OXPHOS defect, 
respiration of m.8344A>G Yellow cells was compared to the one in untransfected cells. Respiration was 
inhibited by Oligomycin and the stimulated by multiple additions of the uncoupler CCCP. Maximum 
respiration was increased in Yellow cells (Fig. 4a). The m.8344A>G mutation in tRNALys is known to 
impair mitochondrial translation due to its defective aminoacylation [25]. We measured the steady-state 
levels of two OXPHOS proteins: 1) NDUFB8, a nuclear encoded subunit of Complex I and 2) COXI, an 
mtDNA-coded subunit of Complex IV. Because the protein synthesis defect is relatively mild in 
heteroplasmic cells, we included low concentrations of the mitochondrial protein synthesis inhibitor 
doxycycline (DOX) to stress the defect. As shown in Fig. 4b, the levels of these proteins were decreased 
at lower concentrations of DOX in untransfected cells. Although NDUFB8 is nuclear encoded, the 
steady-state levels of this protein are reduced because it is rapidly degraded if not incorporated into the 
final complex I assembly [26]. Finally, we measured the activity of Complex IV, and found that Yellow 
cells had a significant increase in Complex IV activity (Fig. 4c). 
 Similar results were obtained for when transfecting the m.13531G>A ND5 heteroplasmic cybrid 
cells with our mitoTALEN. Yellow cells respired more robustly (Fig. 5a) and had restored Complex I 
activity (Fig. 5b) when compared to the parental cell line harboring the m.13531G>A mutation in ND5, 
which impairs complex I activity and respiration [16, 17]. As expected, there was no change in complex 
IV activity in Yellow cells (Fig. 5c) because ND5 is a subunit of Complex I. 
 
Optimizing mitoTALENs for gene therapy 
 Although mitoTALENs are promising tools for the genetic therapy of patients with 
heteroplasmic mtDNA mutations, some challenges remain. A technical one is related to the large size of 
mitoTALENs and the requirement for two monomers that make it difficult to package them in many 
vector systems. Because mtDNA is a low complexity genome compared to the nuclear genome, we 
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reasoned that smaller TALE DNA binding domains would still be effective in shifting heteroplasmy, 
without increasing off-site cleavage to the point at which differential cleavage would be lost. The 
original m.8344A>G mitoTALEN sense and antisense monomers, which had 15.5 and 9.5 RVDs, were 
re-designed to have 10.5 and 7.5 RVDs, respectively. The binding regions are depicted in 
Supplementary Fig. S5. These shorter monomers were tested for synthesis and for mitochondrial 
localization after transfection into COS7 cells (Supplementary Fig. S6). Heteroplasmic 
transmitochondrial cybrid cell lines carrying the m.8344A>G mtDNA mutation were transfected with 
different combinations of sense and antisense mitoTALEN monomers and Yellow cells compared to 
Black cells to examine potential changes mtDNA heteroplasmy. As shown in Fig. 6, all combinations 
resulted in significant reductions in the mutant load. The combination of the shortest monomers (10.5 
and 7.5 RVDs) was perhaps the least robust, with more variability among independent experiments, but 
was still able to significantly eliminate mutant mitochondrial genomes (Fig. 6). 
 
Discussion 
 Through these experiments we were able to establish mitoTALEN as a general approach to 
reduce point mutant mtDNA loads in a heteroplasmic environment. We were able to reduce the mutation 
load in cultured cells harboring two clinically-important mtDNA mutations that cause severe 
encephalopathies. The elimination of the target mutant mtDNA was not complete, and we do not have 
an explanation for that. Mitochondrial-targeted restriction endonucleases gave us a more robust 
elimination of the targeted mitochondrial genome [27], suggesting that mitoTALENs are less efficient 
than restriction nucleases to cleave the mtDNA. Although the TALEN architecture involves specific 
binding to 30-40 bases (15-20 per monomer) in most cases[4], the low mtDNA complexity allowed us to 
reduce the binding site down to a total of 17 bases. It appears particularly important to make the binding 
site to the mutated region small, thereby increasing the impact of a single base change. This was 
illustrated by the fact that the m.8344A>G mitoTALEN version A, which had the monomer binding to 
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the mutation harboring 15.5 RVDs, was unable to differentiate mutant and wild-type targets. On the 
other hand, monomers with ≤12.5 RVDs appear to be able to discriminate single base differences. 
However, it is important to emphasize that the location of the discriminating base has a major impact on 
the binding. The importance of binding at different positions of TALEN monomers has been the subject 
of many studies [4, 28], and it is generally accepted that the proximal bases have a higher impact on 
binding [29]. The presence of a T at position 0 is a required feature for most TALEN architectures, 
although in some cases a C at this position was reported as permissible to binding [4], and, different 
specificities for N-terminus binding are being developed [30]. Therefore, whenever possible, we took 
advantage of position T0 as the discriminating one. However, as exemplified by the m.8344A>G 
mutation, this is not always possible. In this particular mutation, we were able to place a C at position 3 
and found that it was able to effectively discriminate between mutant and wild-type mtDNA. However, 
as mentioned above, this was true only when the mitoTALEN monomer binding to the m.8344A>G 
mutant was relatively short (9.5 instead of 15.5 RVDs). This can be explained by the relative importance 
of a position 3 binding among 15 specific others. It is also important to remember that the other (sense in 
this case) monomer has a perfect binding, making cleavage of the mutated region likely. The use of non-
conventional RVDs may also help in the future design of mitoTALENs [31]. 
 The functional assays confirmed the prediction that mitoTALEN-induced heteroplasmy shift 
leads to improved OXPHOS capacity by reverting the original biochemical defect, which can be a 
defective protein synthesis in the case of tRNA gene mutations or enzyme activity of single OXPHOS 
complexes because of a mutation in a protein coding gene. These results open the path for using this 
approach to treat patients with mtDNA mutations. 
 To bring this technology into clinical trials, it is important to improve technical hurdles, such as 
the large size of mitoTALEN monomers. A mitoTALEN monomer with 15.5 RVDs, a CMV promoter 
and a short poly(A) site is approximately 3,200 bp in length. If using recombinant viral delivery, ideally 
all the required information for both monomers should be expressed from a single virion. This creates a 
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challenge for smaller vectors such as AAV. We started addressing this problem by reducing the size of 
the monomers, particularly the discriminating monomer, to very short binding domains. We found that 
even a monomer with 7.5 RVDs could efficiently reduce m.8344A>G mtDNA heteroplasmy ex vivo. 
Although this short monomer worked well with the complementary short monomer of 10.5 RVDs, it 
worked more consistently with the second (common) monomer containing 15.5 RVDs. 
 Although the reduction in size will facilitate technical issues related to vector design, alternative 
architectures, such as zinc finger nucleases (ZFN) that are intrinsically shorter, could also be used [32]. 
In our hands ZFN are more complex to design and modify although it is an architecture also shown to 
work in reducing mtDNA heteroplasmy [33, 34]. The other alternative, CRISPR poses a challenge for 
mtDNA use, as it requires the import of an RNA component. Our attempts to use this latter platform to 
change mtDNA heteroplasmy have failed (unpublished observations). 
 In summary, mitoTALENs employing gain of T or gain of C design principles have the capacity 
to target many clinically relevant mtDNA point mutations. Moreover the use of discriminating 
monomers in the range of 7.5-15.5 RVDs can robustly reduce the levels of mtDNA genomes with 
pathogenic point mutations in heteroplasmic cells and revert the defective OXPHOS phenotypes. This 
approach has the potential of providing an effective treatment to a sub-group of patients with 
mitochondrial diseases. 
 
Material and Methods 
MitoTALEN constructs. 
Custom-made TALE domains were assembled by Cellectis Bioresearch (Paris, France).  We 
designed and constructed plasmids coding for mitoTALEN monomers using the In-Fusion HD cloning 
kit from Clontech Laboratories according to Bacman et al [10]. Modifications included removal of the 
nuclear localization signal, inclusion of a mitochondrial localization signal derived from SOD2 or 
modified COX8A/Su9 tandem MLS, inclusion of a unique immuno-tag in the N terminus of the mature 
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protein (Hemagglutinin (HA) or Flag), inclusion of a 3′ untranslated region from a mitochondrial gene 
known to localize mRNA to ribosomes on mitochondria, inclusion of an independent fluorescent marker 
to select for expression (eGFP in one monomer and mCherry in the other) and inclusion of a recoded 
picornaviral 2A-like sequence (T2A) between the mitoTALEN and the fluorescent marker [10, 22].  
 
Single-strand annealing (SSA assay). 
Single-strand annealing in Saccharomyces cerevisiae was performed as previously described 
[35]. 
Cells, transfection and sorting. 
Heteroplasmic cybrids harboring the m.8344A>G/tRNALys/MERRF point mutation were derived 
from fusions of an osteosarcoma cell line devoid of mtDNA (143B/206 line20) and dermal fibroblasts 
from a patient harboring the point mutation [36]. Likewise, cybrids cells harboring the ND5 
m.13513G>A mutation were produced by fusing dermal fibroblasts with 143B/206 line20. The clinical 
features of the patient and manipulations to obtain clones with high levels of heteroplasmy are described 
in Supplementary Text. 
Cells were transfected with GenJet DNA In Vitro Transfection Reagent version II (SL100489; 
SignaGen Laboratories) following the protocol suggested by the manufacturers. After 48 h, cells were 
sorted using a FACSAria IIU by gating on single-cell fluorescence using a 561-nm laser and 600LP, 
610/20 filter set for mCherry and a 488-nm laser and 505LP, 530/30 filter set for eGFP. 
 
Mitochondrial expression of the mitoTALENs 
For western blot studies, we subjected 40 µg of total proteins from cellular homogenates of 
COS7 cells collected 48 h after transfection to electrophoresis in 4–20% Tris-HCl polyacrylamide gels 
(4561094; Bio-Rad Laboratories) and transferred the separated proteins to nitrocellulose membranes 
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(162-0115, Bio-Rad), as described [27]. Antibodies used for blotting were rat monoclonal antibody to 
HA (1867423; Roche Biochemical; 1:1,000), mouse monoclonal antibody to Flag (F3165; Sigma-
Aldrich; 1:1,000) and mouse monoclonal antibody to tubulin (T9026; Sigma-Aldrich; 1:1,000) and 
polyclonal antibody against actin (A2066; Sigma-Aldrich 1:1,000). Secondary antibodies were IRDye 
800–conjugated antibody to rat IgG (612-732-120; 1:5,000), IRDye 800–conjugated antibody to mouse 
IgG (610-732-124; 1:5,000) and IRDye 700–conjugated antibody to mouse IgG (610-430-002; 1:5,000) 
from Rockland. An Odyssey Infrared Imaging System (LI-COR) was used to scan the blots. 
To test for mitochondrial internalization of mitoTALEN monomers, HEK293T cells (6 x T75 
flasks) were tranfected with a plasmid coding for a FLAG-tagged MERRF mitoTALEN monomer 
(version C, 7.5 RVDs). After 24 hours, cells were disrupted by nitrogen cavitation and mitochondria 
were isolated by differential centrifugation as described in Adachi et al. [37]. Isolated mitochondria was 
treated with 5 or 50 µg/ml proteinase K on ice for 30 minutes. Samples were analyzed by western blot as 
described above. Antibodies used for blotting were mouse monoclonal antibody to Flag (F3165; Sigma-
Aldrich; 1:1,000) and rabbit monoclonal antibody to VDAC1 (#4661; Cell Signaling, 1:2000). 
For immunocytochemical studies we plated COS7 cells onto coverslips and then transfected 
them with mitoTALEN plasmids as described above. At 24 h post transfection cells were incubated for 
30 min at 37 °C with 200 nM MitoTracker Red CMXRos (Invitrogen) and fixed with 2% 
paraformaldehyde in PBS for 20 min. After a brief treatment with methanol (5 min), primary antibodies 
to HA (Roche; 1:200) or Flag (Sigma-Aldrich; 1:200) in 2% BSA in PBS were incubated overnight at 4 
°C in a humid chamber. The next day, coverslips were incubated for 2 h at room temperature with Alexa 
Fluor 488–conjugated goat antibody to rat IgG (A-11006; Molecular Probes; 1:200) or Alexa Fluor 488–
conjugated goat antibody to mouse IgG (A-11001; Molecular Probes; 1:200), as previously described 
[27]. Images were recorded using a Zeiss LSM510 confocal microscope. 
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Quantification of m.8344A>G and m.13513G>A mutation load by 'last-cycle hot' PCR and RFLP. 
We determined the levels of the m.8344A>G and m.13513G>A mutations by 'last-cycle hot' 
PCR [38] which visualizes only nascent amplicons and removes interference from point mutation 
heteroduplexes formed during melting and annealing cycles. Total genomic DNA was extracted from 
FACS sorted cells with the NucleoSpin Tissue XS kit (740901.50; Macherey-Nagel, Clontech) 
according to the manufacturer's instructions. DNA was used as template, and PCR was performed with 
the following mtDNA primers: 
The mutant allele for the m.8344A>G mutation completes a mismatched primer with a BglI half-
site after PCR amplification, creating a restriction-fragment length polymorphism. The following 
primers were used: B-5’-GTAGTATTTAGTTTGGGGCATTTCACTGTAAAGCCGTGTTGG-3’;  
F- 5′-CTACCCCCTCTAGAGCCCAC-3′ and PCR products were digested with BglI.   
For the m.13513G>A, the mutant allele m.13513G>A completes a mismatched primer with a 
MboI half-site after PCR amplification, creating a mismatch sequence allowing a restriction-fragment 
length polymorphism. B-5’-
ATAGATAGGGCTCAGGCGTTTGTGTATGATATGTTTGCGGTTTCGATGATGTGAT-3’; F-5’-
TCCATCATCCACAACCTTAACAATGA-3’. The resulted amplicons were digested with MboI. The 
digested products were resolved in a 12% polyacrylamide gel. Radioactive signal was quantified using a 
Cyclone phosphorimaging system (PerkinElmer) and OptiQuant software (PerkinElmer). 
 
Sequencing 
Samples were sequenced using ABI BigDye chemistry according to manufacturer’s procedure. 
Sequences were aligned using CLCBio Main Workbench (Qiagen). 
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OXPHOS proteins expression under doxycycline treatment 
Sorted cells after the m.8344A>G/MERRF mitoTALEN transfection were allowed to grow for 
14 days. Both m.8344A>G untransfected and “Yellow” sorted cells were treated with increasing 
concentrations of Doxycycline (D-9891; Sigma-Aldrich)(0-15 µg /ml) for 72h. Cell homogenates (40 µg 
of total proteins) were subject to electrophoresis in 4–20% Tris-HCl polyacrylamide gels (4561094; Bio-
Rad Laboratories) and transferred to nitrocellulose membranes (162-0115, Bio-Rad), then blotted with 
MTCO1 (ab-14705; Abcam), NDUFB8 (ab-110242; Abcam) and α−Tubulin (T9026; Sigma-Aldrich) 
primary antibodies followed by anti-mouse IgG-HRP linked secondary antibody (7076, Cell Signaling). 
 
Measurement of cell respiration. 
Cells in exponential growing phase were collected and respiration rate of intact cells was 
measured at 37 °C with Oroboros high-resolution respirometer Oxygraph-2k (Oroboros Instruments 
GmbH, Austria) [39]. Besides the endogenous respiration, oligomycin-resistant respiration in the 
presence of 1 µg /ml Oligomycin (O-4876, Sigma-Aldrich) and uncoupled respiration with 1 µl of 
0.1mM of CCCP were also recorded (0.05 µM/step) [40]. Data was analyzed with DatLab 4 software 
(Oroboros Instruments, Austria). 
 
Enzyme activities. 
For spectrophotometric analysis, we subjected 9 × 106 exponentially growing cells to 
centrifugation and washed them once with PBS. The pellets were resuspended in 500µl of 20mM MOPS 
(pH 7.4), 100mM Sucrose, 1mM EGTA, 10mM Triethanolamine, 5% Percoll, proteases inhibitors and 
Bovine Serum albumin 1g/liter. Cells were disrupted by cavitation (600psi for 30 min) and mitochondria 
were obtained as described in Adachi et al. [37]. Complex I (NADH CoQ oxidoreductase) reaction was 
started with coenzyme Q1 (100µM) (C7956, Sigma-Aldrich) and inhibited with rotenone (10µM) 
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(R8875, Sigma-Aldrich)[41]. Complex IV reaction was assayed using reduced Cytochrome C (2mM) 
(C2506, Sigma-Aldrich) and Citrate synthase reaction was started with Oxalacetate (0.5mM) (O-4126, 
Sigma-Aldrich))[42]. Assay results were normalized to protein concentration obtained using the BioRad 
Bradford Assay Kit and BSA as standard, and subsequently Complex I and IV activities were 
normalized to Citrate synthase activity. Assays were performed in a BioTek Synergy H1 hybrid plate 
reader. 
 
Statistical analyses. 
Pairwise comparisons were performed using two-tailed Student's t-test using GraphPad Prism 
(GraphPad Software, Inc.) and SPSS package (v.22, IBM). ANOVA was performed with SPSS.  
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Fig. legends 
 
Fig. 1. Development of mitoTALEN for two pathogenic mtDNA mutations. 
(a) The structure of the mitoTALEN monomers is illustrated. They contain a mitochondrial localization 
signal (MLS), an immunological tag (FLAG or HA) and the TALE DNA binding domain. The latter is 
fused to a FokI that works as a heterodimer (EL only dimerizes with KK). (b) Using the established 
TALE code, we designed TALE binding domains against mtDNA regions harboring two pathogenic 
mutations. The first region was at position m.8344A>G in the tRNALys gene, which is associated with 
the MERRF syndrome. The second region, surrounding position m.13513G>A in the ND5 gene is 
associated with MELAS/Leigh syndrome. We have designed two pairs for each region. The figure 
shows only one for each, but the second pair is described in supplementary Fig. S1. The base pair at 
position T0 is shown in green color and the mutated position in red (when they coincide they are labeled 
red). Arrows indicate the mutated base pair. 
 
Fig. 2. mitoTALEN monomers are expressed and localized in mitochondria. (a) Taking advantage 
of the immune tags, we transfected COS7 cells with the respective pair of plasmids coding for the 
m.8344A>G mitoTALEN monomers. After 48 hours, we immunostained the cells with antibodies 
against FLAG or HA depicted in green. Cells were incubated with mitotracker red before fixation. DAPI 
was used for nuclear staining. Western blots (left panels) showed the presence of specific proteins. 
Double bands may indicate incomplete removal of the MLS. (b) The same experiment described above 
was performed for the mitoTALEN monomers against the m.13513G>A mtDNA mutation. Molecular 
weight of the different monomers were: m.8344A>G-15.5 RVDs=102.5KDa; m.8344A>G-9.5 
RVDs=92.5KDa; m.13513G>A-15.5 RVDs=102.5KDa; m.13513G>A-9.5 RVDs=92.5KDa. 
Normalization was done with monoclonal actin antibody.  
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Fig. 3. mitoTALEN against single nucleotide changes can effectively reduce mutant mtDNA loads. 
(a) Transmitochondrial cybrids harboring heteroplasmic levels of the m.8344A>G mtDNA mutation 
were simultaneously transfected with two plasmids, coding for the two mitoTALEN monomers. After 48 
hours cells were sorted for the fluorescent markers and the sorted population expressing both monomers 
(mCherry and eGFP) were referred to as the “Yellow” population (both fluorescent markers). The 
mtDNA heteroplasmy in these cells was compared to the one in the “Black” population (sorted cells 
with no detectable fluorescence, Supplementary Fig. S4). Sorted cell populations had their DNA 
extracted were analyzed by PCR/RFLP as described [10] after digestion with BglI to differentiate the 
mutant from the WT load. (b) Comparison of change in heteroplasmy at 2, 15 or 30 days. (c) The same 
experiment was performed for transmitochondrial cybrids harboring the m.13513G>A mutation with 
two different pair of mitoTALENs, using MboI digestion. The gel illustrates the results with one pair, 
whereas the quantification shows the results for both (mean±SD; n=3). The binding region for the 
different monomers is described in Fig. 1 and Supplementary Fig. S1. 
 
Fig. 4. Functional recovery of mitoTALEN-treated MERRF m.8344A>G tRNA lysine 
transmitochondrial cybrids. (a) Transmitochondrial cybrids harboring heteroplasmic levels of the 
m.8344A>G mtDNA mutation were treated with mitoTALEN and the “Yellow” population expanded 
for 14 days. Cells were assayed for oxygen consumption and compared with the parental line. 
Oligomycin was used to inhibit respiration. To determine the maximum respiration, the uncoupler CCCP 
was added in a stepwise manner. Quantification of the respiratory rates (endogenous and maximal) is 
depicted in the lower part of panel a. (b) The same cells were analyzed for the steady-state levels of 
OXPHOS proteins by western blot. To exacerbate the defect, cells were treated with different 
concentrations of doxycycline for 72h, a mitochondrial protein synthesis inhibitor. (c) Enzymatic 
activity of complex IV (CIV) and citrate synthase (CS) were measured spectrophotometrically in 
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mitochondria from cultured cells treated (Yell) and untreated (Unt) with mitoTALENs and in 143B 
osteosarcoma control line. Values of specific activity of CIV/CS in the ND5 mutant clone were 
compared with the values in mutant clone after TALEN treatment. Panel a:mean±SD; n=3; t-test. Panel 
c: mean±SEM; n=3; ANOVA, Tukey post hoc. 
 
Fig. 5. Functional recovery of mitoTALEN-treated MELAS/Leigh Syndrome m.13513G>A ND5 
transmitochondrial cybrids. (a) Transmitochondrial cybrids harboring heteroplasmic levels of the 
m.13513G>A mtDNA mutation were treated with mitoTALENs and the “Yellow” (Yell) population 
expanded for 14 days. Cells were assayed for oxygen consumption and compared with the untreated 
parental line (Unt.). (b) The activity of Complex I and cytochrome oxidase (Panel c) was measured in 
these cells, plus a 143B osteosarcoma control line, using spectrophotometric assays. Values were 
normalized to citrate synthase activity. Error bars correspond to mean±SEM; n=3; ANOVA, with Tukey 
post hoc. 
 
Fig. 6. Shorter mitoTALENs can effectively reduce mutant mtDNA loads. We compared the original 
functional m.8344A>G mitoTALEN monomers, having 15.5 or 9.5 RVDs, with shorter monomers of 
10.5 and 7.5 RVDs, respectively. The specific binding sites are described in Supplementary Fig. S4 and 
Methods. All different combinations between sense and antisense monomers promoted reduction in 
mutant loads, as shown by comparing heteroplasmy in “Black” and “Yellow” sorted cell populations. 
The bar graph represents 3 independent experiments (mean±SEM; n=3). 
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